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Mutation of the p53 gene in human astrocytic tumours
correlates with increased resistance to DNA-damaging
agents but not to anti-microtubule anti-cancer agents
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Summary Astrocytic tumours often become resistant to a variety of chemotherapeutic agents in advanced stages and frequently possess
mutations in the p53tumour-suppressor gene. Previous studies using established cell lines to investigate the relation between mutated p53
genes and altered resistance to anti-cancer agents brought inconsistent results. In this report, we examined the status of the p53 gene in 56
astrocytic tumour specimens by single-strand conformation polymorphism and their in vitro chemosensitivity to 30 different kinds of anti-
cancer agents. The chemosensitivity was determined by drug-induced cell death using flow cytometry. We found that the mutated p53 gene
correlated with increased resistance to DNA-damaging agents but the sensitivity to anti-microtubule agents was independent of the mutation,
suggesting a clinical significance of the status of p53 gene in astrocytic tumours and a rational application of anti-microtubule agents to the
patients with p53-mutated astrocytic tumours.
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The p53 gene is a tumour-suppressor gene that is frequently
mutated in various human cancers, including astrocytic tumours
which make up more than 60% of primary brain tumours. The
5-year survival rate of the most malignant type, glioblastoma
multiforme, is less than 5% (Walker et al, 1980), and this devas-
tating outcome is ascribed to marked resistance to chemotherapy
and radiotherapy. Wild-type p53 gene product functions as a
checkpoint control protein and is responsible for GI arrest that is
observed at the time of DNA damage (Lane, 1992). The inhibition
of the cell cycle after DNA damage allows more time for DNA
repair, however, if optimal repairs are not accomplished p53 can
trigger a putative apoptotic pathway and eliminate damaged cells.
Recent studies have demonstrated that DNA-damaging stimuli
elevated the intracellularp53 protein level (Kasten et al, 1991) and
that the induction of apoptosis by chemotherapeutic agents was
affected by the status of thep53 gene (Lowe et al, 1993; Fujiwara
et al, 1994). Consequently, tumour cells lacking functional p53
protein become resistant to a variety of chemotherapeutic agents.
Several lines of study have supported this notion (Ass et al, 1996;
Perego et al, 1996). In contrast, increased sensitivity to paclitaxel
or cisplatin was observed in primary or non-transformed cells
without functional p53 protein (Hawkins et al, 1996; Wahl et al,
1996). This discrepancy may be attributable to alterations in genes
other than thep53 gene and/orcell type specificity. In addition, the
action mechanism of anti-cancer agents is also a crucial factor
influencing chemosensitivity.
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In this study, we investigated a possible relationship between
the status of the p53 gene in clinical specimens from astrocytic
tumours and their chemosensitivity, with reference to the mech-
anism of pharmacological action. Such an approach using a
number of clinical samples can randomize the effect of cell type
differences derived from undetermined genetic alterations, and
allows us to explore the relationship in human tumours.
MATERIALS AND METHODS
Tumour samples
All the specimens, aseptically obtained from 56 patients, were
reviewed by several neuropathologists and they were diagnosed as
astrocytic tumours according to the WHO classification. They
included seven cases ofgrade II, ten cases of grade III (anaplastic
astrocytoma) and 39 cases ofgrade IV (glioblastoma multiforme).
The specimens were processed both for in vitro chemosensitivity
test and for DNA extraction.
Genomic DNA amplification and single-strand
conformation polymorphism (SSCP) of p53gene
Genomic DNA was extracted from each sample and the primers
used for polymerase chain reaction were the same as reported
previously (Murakami et al, 1991) except exon 7, for which
5'-TGCCACAGGTCTCCCCAAGG-3', 5'-TATGGAAGAAATC-
GGTAAGA-3' were used for sense and antisense primers respec-
tively. Amplification of DNA was performed as described
previously (Murakami et al, 1991), and the products were
subjected to electrophoresis in a 5% polyacrylamide gel.
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Chemosensitivity test of brain tumours with flow
cytometry
Surgically resected tumour cells were minced and suspended in
RPMI-1640 medium with 10% fetal calf serum. The viability in
each preparation was examined using a dye exclusion test and was
constantly over 95%. An aliquot of the cell suspension was incu-
bated individually with 30 different agents classified as six types;
4-hydroperoxycyclophosphamide (CPM) (10 jg ml-'), 4-hydro-
peroxyifosfamide (IFOS) (10 jg ml-'), melphalan (MPL)
(0.5 jig ml-'), carboquone (CQ) (0.1 ,ug ml-'), nimustine (ACNU)
(2 jig ml-') and ranimustine (MCNU) (2 jg ml-') as alkylating
agents; methotrexate (MTX) (3 jg ml-'), 5-fluorouracil (5-FU)
(10 jig ml-'), thioinosine (6-MPR) (3 jig ml-') and cytosine arabi-
noside (CA) (4 jg ml-') as anti-metabolites; mitomycin C (MMC)
(0.2 jg ml-), bleomycin (BLM) (1 jig ml-'), peplomycin (PEP)
(0.5 jig ml-'), chlomomycin A3 (TM) (0.01 jg ml-') and neocarzi-
nostatin (NCS) (0.15 jig ml-') as antibiotics; actinomycin D
(ACD) (0.01 jig ml-'), aclarubicin (ACR) (0.6 jg ml-'), doxoru-
bicin (DOX) (0.3 jig ml-'), daunomycin (DM) (0.6 jig ml-'),
pirarubicin (THP) (0.3 jg ml-'), epirubicin (4'-EPI) (0.4 jg ml-'),
mitoxantrone (MIT) (0.06 jg ml-'), etoposide (VP-16) (3 jg ml-')
and camptothecin (CPT- 11) (3 jg ml-') as topoisomerase
inhibitors; cisplatin (CDDP) (0.5 jg ml-') and carboplatin (JM-8)
(4 jg ml-') as platinum agents; vincristine (VCR) (0.1 jg ml-'),
vinblastine (VLB) (0.1 jg ml-'), vindesine (VDS) (0.1 jig ml-')
and paclitaxel (TAX) (0.6 jig ml-') as anti-microtubule agents.
Each concentration tested corresponds to one-tenth of the peak
plasma concentration ofclinically recommended doses. Cells were
incubated with each agent at 37°C in 5% carbon dioxide for 8 h,
and then cultured in fresh RPMI-1640 medium for 72 h. They
were mixed in phosphate buffered-saline pH 7.2, 0.1% Triton
X-100, 0.1 mg ml-' RNAase, 0.01% sodium azide for 15 min, and
were incubated with 100 jig ml-' propidium iodide (Sigma,
St Louis, MO, USA) for 5 min. Isolated nuclei were analysed with
a flow cytometer (FACScan: Becton Dickinson, Mountain View,
CA, USA) (Nicoletti et al, 1991; Iwadate et al, 1997). Our
previous study showed that the results obtained with the concen-
tration used in this assay could represent the data from various
concentrations ofthe agents (Iwadate et al, 1997).
Statistical analysis
Statistical analysis was performed with Fisher's exact probability
test, Mann-Whitney test or Mantel-Haenszel X2 test.
RESULTS
The status of the p53 gene of astrocytic tumours was examined
by SSCP on amplified genome DNA products. Among 56
samples tested, we detected altered electrophoretic mobility in
23 samples (41%), which included six cases of dual mutations
(Table 1). The frequency of the mutated p53 gene in grade II
astrocytic tumours was relatively great compared with that of
grade III or IV cases without statistical significance (P = 0.09,
Fisher's exact probability test). The overall mutation rate in
astrocytic tumours matched with previous reports (Lang et al,
1994), but the reason for the high mutation rate in grade II cases
is currently unknown.
We also examined the chemosensitivity ofthe specimens to 30
different anti-cancer agents. The agents used here are clinically
Table 1 Frequency of the mutated p53 gene in patients with astrocytic
tumours
Grade
11 III IV
Number of patients 7 10 39
Status of the p53gene
Wild-type 2 8 23
Mutated 5 (71%) 2 (20%) 16 (41%)
Exons5and 6 1 1 6
Exon7 5 2 11
Exons8and 9 2 0 1
in use and classified into six types based on the mechanism of
action (see Materials and methods). The chemosensitivity was
assayed by flow cytometrical analysis after staining with
propidium iodide (Figure 1). The technique enables us to detect
nuclear degradation that appears as a hypodiploid peak and
represents DNA fragmentations induced by apoptotic process
(Nicoletti et al, 1991). We judged the agent as effective in cases
in which more than a 70% reduction of the integrated diploid
peak compared with that of untreated control cells was observed
(Iwadate et al, 1997). The increase in the hypodiploid area corre-
sponded to the decrease in the number oflive cells. Our previous
dose-response experiment showed that the result obtained by the
present method using a single dose point could represent the data
accumulated using different concentrations of the agents
(Iwadate et al, 1997).
The number of agents judged as effective varied among each
sample tested, but the mean percentage of effective agents in
the mutated and the wild-type groups of the p53 gene was
4.2 ± 1.1% (s.e.) and 17 ± 2.2% respectively (Table 2). Thus, the
mutation in the p53 gene confers increased resistance to
chemotherapeutic agents with statistical significance (P < 0.01,
Mann-Whitney test).
We analysed the relationship between the susceptibility to each
agent and the status ofthep53 gene based on the mode ofpharma-
cological action (Table 2). Although the number of effective
agents varied among the specimens, the percentage of effective
agents that belong to DNA-damaging types (alkylating agents,
anti-metabolites, antibiotics and topoisomerase inhibitors) was
higher in the wild-type than in the mutated cases (P < 0.01 in every
type, Mantel-Haenszel X2 test), regardless of the nature of
compounds. In the case of platinum agents, another DNA-
damaging type, the statistical significance was not proved (0.05 <
P < 0.06), Mantel-Haenszel X2 test); however, we observed the
same tendency as in the high number of effective agents in the
wild-type. Consequently, all the DNA-damaging agents tested,
including platinum agents, were less effective in thep53-mutated
cases (3.0 ± 1.0%) than in the wild-type p53 cases (18 ± 2.4%)
(P < 0.01, Mann-Whitney test). In contrast, the percentage of
effective agents that act on microtubules was not different between
the cases (12 ± 2.7% for p53-mutated cases and 8.3 ± 3.1% for
wild-type cases). Among the mutated cases, the percentage of
effective drugs that belong to anti-microtubule agents was higher
than that to other types (12 ± 2.7% vs 3.0 ± 1.0%, P < 0.01,
Mann-Whitney test). Thus, these data collectively suggest that the
mutation in thep53 gene confers resistance to DNA damage-based
agents but not to anti-microtubule agents.
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Figure 1 A representative flow cytometrical analysis of specimens with mutated p53 (A) or wild-type p53 gene. Sample A was resistant to all the agents
except TAX, whereas sample B was sensitive to CPM, BLM, ADM but not to CA, CDDP and TAX. The abscissa represents fluorescence intensity and the
ordinate represents cell number. Abbreviations of drug names are explained in Materials and methods
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Table 2 In vitro chemosensitivity of astrocytic tumour patients to various anti-cancer agents
Number of effective agents
Agents Mutated p53(n = 23) Wild-type p53(n = 33)
(per cent of effective agents ± s.e.) (percent of effective agents ± s.e.)
Alkylating agents (X2 = 12.2, d.f. = 1, P< 0.01)a
CPM 0
IFOS 1
MPL 0
CQ 0
ACNU 0
MCNU 2
Subtotal (2.2 ± 1.5%)
Anti-metabolites (X2 = 13.2, d.f. = 1, P < 0.01)a
MTX 1
5-FU 0
6-MPR 0
CA 0
Subtotal (1.1 ± 1.1%)
Antibiotics (X2 = 10.8, d.f. = 1, P< 0.01)a
MMC 0
BLM 0
PEP 0
TM 0
NCS 0
Subtotal (0 ± 0%)
Topoisomerase inhibitors (X2 = 33.5, d.f. = 1, P < 0.01)a
ACD 1
ACR 5
DOX 2
DM 0
THP 1
4'-EPI 1
MIT 1
VP-16 2
CPT-l1 0
Subtotal (6.3 ± 2.2%)
Platinum agents (X2 = 3.76, d.f. = 1, 0.05 < P < 0.06)a
CDDP 0
JM-8 1
Subtotal (2.2 ± 2.2%)
Anti-microtubule agents (X2 = 0.450, d.f. = 1, P > 0.1 )a
VCR 3
VLB
VDS
TAX
Subtotal
Total
4
3
(12 ± 2.7%)
(4.2 ± 1.1%)b
9
9
2
1
2
4
(14 + 4.5%)
3
2
4
13
(17 ± 7.7%)
4
3
6
3
1
(10 ± 2.5%)
4
15
10
11
10
10
5
11
3
(27 + 4.0%)
7
3
(15 ± 6.1%)
5
0
3
3
(8.3 ± 3.1%)
(17 ± 2.2%)b
Abbreviations of the agents names are explained in Materials and methods. aMantel-Haenszel X2 test.
bp< 0.01, Mann-Whitney test.
DISCUSSION
In this study we have shown that the chemosensitivity ofastrocytic
tumours to DNA-damaging agents but not to anti-microtubule
agents is influenced by the status of thep53 gene. The role of p53
protein in the sensitivity to chemotherapeutic agents that include
anti-microtubule agents is controversial (Lowe et al, 1993;
Wosikowski et al, 1995; Della et al, 1996; Hawkins et al, 1996;
Perego et al, 1996; Wu and El-Deiry, 1996). Overexpression ofthe
wild-type p53 gene increased the sensitivity in some experiments
(Fujiwara et al, 1994) butinactivation ofthe wild-typep53 gene did
not always decrease the sensitivity (Hawkins et al, 1996; Wu and
El-Deiry, 1996). Several reasons for the inconsistent results have
been put forward: (a) species and/or cell type specificity used in
various experimental system (Della et al, 1996; Wu and El-Deiry,
1996); (b) additional genetic changes acquired during the process
ofestablished cell lines; and (c) genetic instability incurred by loss
offunction of thep53 gene (Livingstone et al, 1992). Examination
of a number of clinical specimens as presented in this report, even
although heterogeneity of clinical cases is unavoidable, can
circumvent the above arguments and evaluate the clinical impor-
tance ofthe mutatedp53 gene in a certain malignancy.
There are two types of anti-microtubule agents regarding their
action mechanisms, i.e., depolymerization and stabilization of
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microtubules. Vinca alkaloids such as vinblastine and vincristine
depolymerize microtubules and induce the arrest of the cell cycle
at the mitotic stage. In contrast, paclitaxel binds directly to poly-
merized tubulins and impels cell cycle blockage during mitosis by
promoting the microtubule assembly and inhibiting the disas-
sembly (Horwitz, 1992). As both types primarily induce dysfunc-
tion of microtubules rather than direct DNA damage and prevent
the completion of mitosis, consequent cell death would be less
dependent on functional p53. In fact, increased p53 by genotoxic
agents preferentially induces G, arrest rather than G2/M arrest
(Jacks and Weinberg, 1996). Accordingly, p53 may be less
involved in apoptotic pathways during G2/M phase triggered by
chemotherapeutic agents (Wahl et al, 1996).
Our present results show that the role ofp53 in chemosensitivity
depends on the type of agents, and suggest clinical benefits of the
regimens including anti-microtubule agents to the patients with
p53-mutated tumours who are not susceptible to DNA damage-
based therapies. Current clinical trials of paclitaxel in brain
tumours suggest that paclitaxel can cross the blood-brain barrier
(Chamberlain and Kormanik, 1995; Glantz et al, 1996a) and that
the status of the p53 gene may influence the responsiveness
(Glantz et al, 1996b). Randomized clinical trials regarding the
mutation and the chemotherapy based on its sensitivity test will be
an important step in future.
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